Skip to main content
Clinical Trials/NCT06165718
NCT06165718
Recruiting
Not Applicable

A Multicenter, Observational Study for the Clinical Roadmap and Prognosis of Pulmonary Artery Sarcoma.

China-Japan Friendship Hospital1 site in 1 country120 target enrollmentDecember 31, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pulmonary Artery Sarcoma
Sponsor
China-Japan Friendship Hospital
Enrollment
120
Locations
1
Primary Endpoint
Progression-free survival
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

This is an observational study in which patients with pulmonary artery sarcoma were followed up for at least 36 months and survival was investigated.

Detailed Description

This is an observational study covering mainland China, and patients with pulmonary artery sarcoma were followed up for at least 36 months and survival was investigated.

Registry
clinicaltrials.gov
Start Date
December 31, 2022
End Date
June 30, 2025
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
China-Japan Friendship Hospital
Responsible Party
Principal Investigator
Principal Investigator

Wanmu Xie

Professor

China-Japan Friendship Hospital

Eligibility Criteria

Inclusion Criteria

  • Computed tomography pulmonary angiography indicated that there were intraluminal defects
  • Malignant histopathology was sarcoma
  • Informed consent form was signed

Exclusion Criteria

  • Life expectancy was less than 3 months due to diseases other than pulmonary artery sarcoma
  • Expected inability to complete follow-up

Outcomes

Primary Outcomes

Progression-free survival

Time Frame: 36 months

Time to death or disease progression

Secondary Outcomes

  • Postoperative survival(36 months)
  • Overall survival(36 months)

Study Sites (1)

Loading locations...

Similar Trials